In Q4 2025, Ironwood generated total revenue of 47709000, reported a GAAP net loss of 2276000, and recorded adjusted EBITDA of 10913000, reflecting lower LINZESS U.S. net sales and a decline in commercial margin.

Ironwood Pharmaceuticals delivered robust Q3 2025 results, highlighted by a 40% YoY growth in LINZESS U.S. net sales, record adjusted EBITDA, and a surge in GAAP net income. The company raised its full-year 2025 guidance across all key financial metrics.

In Q2 2025, Ironwood reported total revenue of 85239000, GAAP net income of 23599000 with diluted EPS of 0.14, non-GAAP net income of 23623000, and strong LINZESS U.S. net sales of 248000000 driven by 10% prescription demand growth and a 69% commercial margin. :contentReference[oaicite:0]{index=0}

Ironwood Pharmaceuticals reported a total revenue of $41.1 million and a GAAP net loss of $37.4 million for the first quarter of 2025. The company's LINZESS prescription demand grew by 8% year-over-year, and they raised their adjusted EBITDA guidance for 2025 to greater than $105 million. The decrease in revenue was primarily due to a change in estimate of AbbVie gross-to-net rebate reserves, which is expected to impact quarterly phasing but not full-year results.

Ironwood Pharmaceuticals reported its fourth quarter and full year 2024 results, highlighting progress with apraglutide and continued LINZESS demand growth. The company is preparing for the potential launch of apraglutide and streamlining operations for long-term value creation.

Ironwood Pharmaceuticals reported its third quarter 2024 results, highlighting a 13% year-over-year growth in LINZESS prescription demand. The company is maintaining its full year financial guidance and is on track to complete the apraglutide NDA submission in Q1 2025.

Ironwood Pharmaceuticals reported its second quarter 2024 results, noting an 11% year-over-year increase in LINZESS prescription demand and a 15% increase in new-to-brand growth. The company is facing continued pricing pressure on LINZESS due to higher-than-expected Medicaid utilization trends. Ironwood plans to pursue apraglutide rolling NDA review and expects to complete submission in the first quarter of 2025. They are also on track to deliver CNP-104 topline results in the third quarter of 2024.

Ironwood Pharmaceuticals reported its first quarter 2024 results, highlighting significant advancements across its portfolio, including positive Phase III clinical data for apraglutide and strong LINZESS demand momentum. The company is working swiftly to file an NDA for apraglutide for adult SBS patients dependent on parenteral support and revised FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate.

Ironwood Pharmaceuticals reported its fourth quarter and full year 2023 results. LINZESS U.S. net sales reached $1.1 billion, a 7% increase year-over-year, driven by EUTRx prescription demand growth of 10% year-over-year. Ironwood's revenue was $443 million, primarily driven by $430 million in U.S. LINZESS collaboration revenue.

Ironwood Pharmaceuticals reported its third quarter 2023 results, highlighting an 8% year-over-year increase in LINZESS EUTRx prescription demand and a 7% year-over-year increase in LINZESS U.S. net sales, which reached $279 million. The company also announced positive final data from the STARS Nutrition study and anticipates topline data for the Phase II study of CNP-104 in Q3 2024.

Ironwood Pharmaceuticals reported strong second-quarter results, driven by LINZESS's impressive performance. The company raised its full-year 2023 U.S. net sales and Ironwood revenue guidance. The FDA approved LINZESS for pediatric patients, and Ironwood acquired VectivBio, strengthening its GI portfolio.

Ironwood Pharmaceuticals reported a strong start to the year with increased LINZESS prescription demand and U.S. net sales. The company ended the quarter with a solid cash position and is progressing with its pipeline programs.

Ironwood Pharmaceuticals reported its fourth quarter and full year 2022 results, with full year LINZESS U.S. net sales growth lower than expected due to inventory fluctuations, but delivered adjusted EBITDA guidance of over $250 million. The company ended the year with a strong balance sheet and is focused on investing in LINZESS and pursuing GI assets.

Ironwood Pharmaceuticals reported strong Q3 2022 results, with LINZESS exceeding 1 million total prescriptions in a quarter and a 10% year-over-year increase in EUTRx prescription demand. GAAP net income was $50 million, and adjusted EBITDA was $69 million, with $574 million in cash and cash equivalents at the end of the quarter. The company maintains its full-year 2022 financial guidance.

Ironwood Pharmaceuticals reported positive momentum in Q2 2022, with LINZESS prescription demand growth and progress in clinical trials. The company ended the quarter with $504 million in cash and cash equivalents and reiterated its 2022 full-year guidance.

Ironwood Pharmaceuticals reported its first quarter 2022 results, featuring an 11% year-over-year increase in LINZESS® prescription demand and U.S. LINZESS® net sales of $232 million, an 8% increase year-over-year. The company reported total revenue of $98 million, GAAP net income of $39 million, and adjusted EBITDA of $58 million, ending the quarter with $593 million in cash and cash equivalents.

Ironwood Pharmaceuticals reported strong Q4 2021 results, driven by the success of LINZESS® which achieved blockbuster status with over $1 billion in U.S. net sales for the year. The company is also advancing its GI pipeline with clinical studies for IW-3300 and CNP-104.

Ironwood Pharmaceuticals reported Q3 2021 results, featuring a 12% year-over-year increase in LINZESS prescription demand, $253 million in LINZESS U.S. net sales (a 5% increase year-over-year), total revenue of $104 million, and GAAP net income of $56 million. The company ended the quarter with $574 million in cash and cash equivalents and expanded its pipeline through an option agreement with COUR Pharmaceuticals.

Ironwood Pharmaceuticals reported a strong second quarter in 2021, with U.S. LINZESS net sales increasing by 18% year-over-year to $259 million and total revenue increasing by 16% year-over-year to $104 million. The company's GAAP net income was $391 million, which included a $338 million non-recurring income tax benefit. Ironwood ended the quarter with $493 million in cash and cash equivalents and raised its full-year 2021 financial guidance.

Ironwood Pharmaceuticals reported a strong start to the year with U.S. LINZESS net sales increasing by 12% year-over-year to $215 million. Total revenue reached $89 million, driven by U.S. LINZESS collaboration revenue. The company ended the quarter with $438 million in cash and cash equivalents and is maintaining its full-year 2021 financial guidance.

Ironwood Pharmaceuticals reported fourth quarter and full year 2020 results, exceeding or meeting full year 2020 financial guidance. The company's performance was driven by U.S. LINZESS net sales growth of 10% year-over-year in 2020. Ironwood delivered its second full year of profits and ended the year with $363 million in cash and cash equivalents.

Ironwood Pharmaceuticals reported a strong third quarter, driven by continued demand for LINZESS, which saw a 10% increase in net sales year-over-year. The company reported profitability and positive cash flow.

Ironwood Pharmaceuticals reported a solid quarter with GAAP net income of $25 million and adjusted EBITDA of $33 million. LINZESS total prescription demand grew by 9% year-over-year.

Ironwood Pharmaceuticals reported a 16% year-over-year increase in total revenue to $80 million for the first quarter of 2020, driven primarily by U.S. LINZESS collaboration revenue of $71 million. The company delivered GAAP net income of $3 million and adjusted EBITDA of $14 million. However, due to COVID-19 uncertainties, Ironwood withdrew the remainder of its previously disclosed 2020 financial guidance, while maintaining its adjusted EBITDA guidance of >$105 million.

Ironwood Pharmaceuticals reported strong fourth quarter and full year 2019 results, exceeding full year 2019 guidance. The company's 2019 revenue was $428 million, driven primarily by U.S. LINZESS collaboration revenue. GAAP net income from continuing operations was $59 million and adjusted EBITDA from continuing operations was $148 million for the full year 2019. 2020 total revenue and adjusted EBITDA guidance incorporates previously amended agreements with Astellas and AstraZeneca. Data readouts from MD-7246 Phase II trial and IW-3718 Phase III trials are expected in 2020.